MK-0812 Succinate - 10mM in DMSO , CAS No.851916-42-2

CAS: 851916-42-2 Cat. No.: M655252 Molecular Weight: 587.63 PubChem CID: 60196412
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Desiccated,Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
M655252-1ml
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$465.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2 .

In Vitro

MK-0812 is a potent and selective CCR2 antagonist. MK-0812 completely blocks all MCP-1 mediated response in a concentration dependent manner, with an IC 50 of 3.2 nM. This value is similar to the potency observed for the inhibition of 125 I-MCP-1 binding by MK-0812 on isolated monocytes (IC 50 4.5 nM). In fact, MK-0812 not only completely blocks the shape change response to exogenous MCP-1, but also results in a monocyte forward scatter measurement below unstimulated or basal levels. The addition of MK-0812 to rhesus blood also inhibits MCP-1 induced monocyte shape change. The IC 50 for MK-0812 in whole blood assays is 8 nMMCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MK-0812 (30 mg/kg, p.o.) reduces the frequency of Ly6G - Ly6C hi monocytes in the peripheral blood, while no impact on circulating Ly6G + Ly6C + neutrophil frequency is observed. In addition, MK-0812 treatment causes a dose-dependent reduction in circulating Ly6C hi monocytes and a corresponding elevation in the CCR2 ligand CCL2 . MK-0812 is administered by continuous i.v. infusion to maintain a constant level of the drug in blood. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:CCR2

Specifications

Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2 .
Storage
Desiccated, Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Names and Identifiers
Isomeric SMILES CC(C)[C@@]1(CC[C@H](C1)[NH2+][C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F.C(CC(=O)[O-])C(=O)O
PubChem CID 60196412
Molecular Weight 587.63

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.